XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio [Yahoo! Finance]
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy [Yahoo! Finance]
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) [Yahoo! Finance]
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts [Yahoo! Finance]
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)